Clinical Trials Lead to Promising Updates in Mesothelioma Immunotherapy
This study recruited patients with unresectable pleural mesothelioma who had not received prior chemotherapy. The primary endpoint of median overall survival was significantly longer with the addition of bevacizumab to chemotherapy at 18.8 months versus 16.1 months with chemotherapy alone. However, adverse events such as hypertension and bleeding were more common in the bevacizumab group. More recently, studies such as the phase II RAMSES trial in 2020 have shown promising results for combining anti-VEGF medication with chemotherapy as a second-line treatment. The addition of the VEGF inhibitor ramucirumab significan...
Source: Asbestos and Mesothelioma News - December 8, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Bevacizumab and Gastrointestinal Perforations Bevacizumab and Gastrointestinal Perforations
This study describes the demographic and clinical characteristics of this serious adverse event.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Bevacizumab-vikg Wet AMD Trial Raises Eyebrows Bevacizumab-vikg Wet AMD Trial Raises Eyebrows
An ' apples-to-oranges ' comparison of bevacizumab-vikg to ranibizumab is troubling some experts who would like to see the drug approved.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2021 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

New Standard of Care in Cervical Cancer New Standard of Care in Cervical Cancer
The combination resulted in significant improvements in both progression-free and overall survival compared with chemotherapy (with or without bevacizumab) alone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 19, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine
Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF), a key mediator of angiogenesis in cancer, and is used in combination with other treatments(1,2). (Source: World Pharma News)
Source: World Pharma News - September 8, 2021 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease
We report the first real-world evidence regarding clinical outcomes for a cohort of patients with advanced MPeM receiving ICIs,” the MD Anderson study authors wrote. “Our results provide much-needed data supporting the role of ICIs in patients with this rare disease, who cannot participate in clinical trials and otherwise have no or limited treatment options.” The post Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - August 31, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

New Drug Combination Shows Promise for Peritoneal Mesothelioma
Researchers at MD Anderson Cancer Center in Houston have uncovered a new, promising treatment option for patients with peritoneal mesothelioma, potentially filling a gaping void that exists today. The immunotherapy drug combination of Tecentriq and Avastin, known generically as atezolizumab and bevacizumab, respectively, showed unusual efficacy in a recent study of 20 patients with this rare cancer. Although some patients have previously found significant success and extended survival with the cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combination, or HIPEC, those with unresectable disease ha...
Source: Asbestos and Mesothelioma News - July 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Oncotarget: RAS reversion in colorectal cancer patients treated with bevacizumab
(Impact Journals LLC) This Oncotarget finding might have potential therapeutic implications, as anti-EGFR could be reconsidered in primarily RAS mutant patients reverted to a wild-type status after bevacizumab exposure. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 16, 2021 Category: Cancer & Oncology Source Type: news

Drug combination shows meaningful responses for malignant peritoneal mesothelioma patient
(University of Texas M. D. Anderson Cancer Center) A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

Edge Pharma Announces New Agreement with Cardinal Health ’s Acuity™ GPO
Edge Pharma, a 503B Outsourcing Facility, has entered into an agreement with Cardinal Health’s Acuity™ GPO to provide its member ophthalmology practices with Edge’s unit-dose MVASI™ (Bevacizumab-awwb)...(PRWeb July 14, 2021)Read the full story at https://www.prweb.com/releases/edge_pharma_announces_new_agreement_with_cardinal_healths_acuity_gpo/prweb18065310.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 14, 2021 Category: Pharmaceuticals Source Type: news

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers
Hematology / Oncology Drug Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Drug Combination Disappoints in Advanced NSCLC Drug Combination Disappoints in Advanced NSCLC
Second-line bevacizumab plus osimertinib showed some PFS benefit over osimertinib alone in a subset of smokers/former smokers but overall showed no survival benefits in the ETOP BOOSTER trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 24, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Intravitreal bevacizumab cost saving for macular oedema in the UK
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2021 Category: Drugs & Pharmacology Source Type: news

Genentech defends breast cancer drug a decade after Avastin drama
"We all want to give patients hope — real hope, not false hope," said one opponent of allowing Genentech's Tecentriq to stay on the market. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 28, 2021 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Genentech defends breast cancer drug a decade after Avastin drama
"We all want to give patients hope — real hope, not false hope," said one opponent of allowing Genentech's Tecentriq to stay on the market. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 28, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news